Cognitive Focus

Archival Status

Semax and Selank represent the most studied peptide pair for cognitive enhancement in Russian neurological research, with decades of clinical application in Eastern European medical systems for conditions ranging from ADHD and cognitive decline to anxiety disorders and ischemic stroke recovery. Semax is a synthetic heptapeptide derived from the ACTH fragment 4-7, modified to resist enzymatic degradation. Its primary mechanism involves upregulation of Brain-Derived Neurotrophic Factor (BDNF) and Nerve Growth Factor (NGF) — neurotrophins critical for synaptic plasticity, neuronal survival, and long-term potentiation. Semax also modulates dopaminergic and serotonergic neurotransmission, influences the expression of genes related to the immune system and cerebral blood flow, and has demonstrated neuroprotective effects in ischemia models. Russian clinical research has shown cognitive improvements in stroke patients and individuals with cerebrovascular disease. Its intranasal administration route allows direct transport across the olfactory epithelium, bypassing the blood-brain barrier. Selank is a synthetic analogue of the endogenous immunomodulatory peptide tuftsin, combined with a stabilizing sequence. It primarily modulates GABAergic neurotransmission to produce anxiolytic effects comparable to benzodiazepines in research models, but without the sedation or dependence potential. Additionally, Selank upregulates enkephalins (endogenous opioid peptides), modulates the expression of interleukins and interferons in the CNS, and has shown cognitive-enhancing properties through BDNF pathway activation — a mechanism it shares with Semax. The synergy between these peptides is complementary rather than redundant. Semax provides the cognitive upregulation (BDNF, focus, processing speed) while Selank addresses the anxiolytic and stress-regulatory component that often limits cognitive performance under real-world conditions. Research suggests optimal cognitive performance requires both adequate neurotrophin support and controlled stress response — the dual-pathway approach of this combination addresses both simultaneously. Research applications include: stress-induced cognitive impairment, anxiety-related performance deficits, post-stroke neurological rehabilitation, ADHD and attention disorders, and general cognitive optimization. Both peptides are administered intranasally, with onset within 20–30 minutes and duration of 4–6 hours per dose.